PIPELINE
Advancing Navacims™ for autoimmune diseases
and chronic inflammatory conditions
Parvus’ pipeline programs address a broad range of autoimmune diseases with compelling unmet needs.
Parvus’ lead Navacim (PVT201) has shown disease modification and hepatoprotection in preclinical models of Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, and Autoimmune Hepatitis. Parvus’ pipeline includes Navacim development programs for IBD, Type-1 Diabetes, Multiple Sclerosis, Rheumatoid Arthritis, transplant rejection prevention, and Celiac Disease.